Generic Name and Formulations:
Niacin 500mg, 750mg, 1g; ext-rel tabs.
Indications for NIASPAN:
Adjunct to diet in primary hyperlipidemia and mixed dyslipidemia to reduce elevated total-C, LDL-C, apo B, TG and to increase HDL-C. To reduce risk of recurrent nonfatal MI in patients with a history of MI and hyperlipidemia. Combined with a bile acid sequestrant to slow progression or promote regression of atherosclerosis in patients with coronary artery disease and hyperlipidemia. Combined with a bile acid sequestrant to reduce elevated total-C and LDL-C in primary hyperlipidemia when diet or diet + monotherapy has been inadequate. Adjunct in patients with severe hypertriglyceridemia who are at risk for pancreatitis, when determined dietary measures are inadequate.
Limitations Of use:
The addition of Niaspan did not reduce cardiovascular morbidity or mortality among patients treated with simvastatin in a controlled trial.
Swallow whole. Take at bedtime with low-fat snack. Avoid concomitant alcohol, hot beverages, or spicy foods; may pre-treat with aspirin (up to 325mg) ½ hour before dosing. >16yrs: initially 500mg once daily for 4 weeks, then 1g once daily for weeks 5–8. May increase by up to 500mg every 4 weeks to usual range of 1–2g daily; max 2g/day. Retitrate if restarting after an extended time. Women may respond at lower doses than men.
≤16yrs: not established.
Active liver disease. Unexplained elevations of serum transaminases. Active peptic ulcer disease. Arterial bleeding.
Do not substitute for equivalent doses of immediate-release or sustained-release niacin (hepatotoxicity may occur). History of jaundice, hepatobiliary disease, peptic ulcer. Substantial alcohol consumption. Monitor serum transaminase levels (before treatment, then every 6–12 weeks for 1 year, then periodically); discontinue if transaminase levels ≥3xULN persist or if signs of liver disease occur. Renal impairment. Cardiovascular disease (eg, unstable angina, acute MI). Gout. Monitor blood glucose and for hypophosphatemia. Surgery. Diabetes or patients at risk for diabetes. Uncontrolled hypothyroidism. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Avoid other products with high amounts of niacin or nicotinamide, alcohol. Monitor for myopathy/rhabdomyolysis with HMG-CoA reductase inhibitors. May potentiate antihypertensives, other vasoactive drugs (eg, ganglionic or adrenergic blockers, nitrates, calcium channel blockers). Caution with anticoagulants (monitor PT and platelet counts). Antidiabetic agents may need adjustment. Separate dosing of bile acid sequestrants by at least 4–6 hours. May cause false (+) Benedict's test.
Nicotinic acid deriv.
Flushing, diarrhea, nausea, vomiting, cough, pruritus, rash, dizziness, tachycardia, palpitations, shortness of breath, sweating, chills, edema, muscle pain; glucose intolerance, abnormal LFTs.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States
- CVS Pharmacy Launches Prescription Delivery Service Nationwide
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit
- Kidney Function Decline Occurs Nearly Twice as Fast in Diabetes